age related macular degeneration

Latest Headlines

Latest Headlines

Regeneron, Bayer reach for the old Eylea magic with combo AMD deal

Partners Regeneron and Bayer are hoping to piggy-back on their success with the wet age-related macular degeneration blockbuster Eylea, reuniting to develop a new drug that could become part of a combination therapy for the disease.

Roche's gRED sees promising results in PhII macular degeneration study

Investigators say that lampalizumab slowed progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20.4%. AMD is a leading cause of blindness and major market opportunity for the drug giant, which has executed a sequence of big advances in R&D.

Ophthotech eyes $85M IPO to fund PhIII for drug to prevent blindness

After assembling a whopping $175 million financing deal this spring, Ophthotech has filed paperwork with the SEC to secure up to $85 million more in an initial public offering.

First successful transplant of retinas made from embryonic stem cells

For the first time, scientists have successfully transplanted light-detecting cells in the retina, grown from embryonic stem cells, into mice--a feat that could eventually lead to new treatments for blindness in humans.

Japan green-lights trial of stem cell therapy for eye disease

Japanese researchers have won permission to embark on a pioneering clinical study of a stem cell therapy for age-related macular degeneration, a major cause of vision loss in aging patients. The planned trial is being hailed as the first human test of a stem cell therapy made from patient's own cells.

Novo spearheads $175M financing to back Ophthotech's PhIII AMD study

New York-based Ophthotech has rounded up a whopping $175 million in financing to cover a pivotal late-stage study of its lead drug for wet AMD. The biotech signed a deal to share its royalties on Fovista--earlier dubbed E10030--with Novo A/S in exchange for $125 million. And Novo stepped up to lead a $50 million Series C round for the company.

Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs

The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

Building on a $420 million deal it already has in place with Switzerland's Molecular Partners, Allergan has come back to the bargaining table to deepen its pipeline for ophthalmic drugs. Allergan paid $62.5 million upfront and promised up to $1.4 billion dollars in milestones in the ambitious deal, which covers a pair of R&D pacts.

Pfizer ($PFE) signs separate agreements with Lpath, Phylogica

Pfizer ($PFE) has had a busy day, signing separate pacts with two biotech companies: one with Lpath for a product candidate to treat ophthalmology disorders, and the other with Australia's Phylogica

ALSO NOTED: ASCO news; Acorda shares surge on data; Genentech, Exelixis and Celgene win kudos; and much more...

> Shares of Acorda Therapeutics shot up after researchers released new late-stage data demonstrating that Fampridine consistently improved the walking speeds of MS patients.